JamesMitchellGranfortunaMDFACP

Hematology • Browns Summit, NC

Associate Professor of Medicine - Internal Medicine Teaching Program ocations at Cone Health Internal Medicine Center

Join to view full profile

Dr. Granfortuna is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Granfortuna's full profile

Already have an account?

Office
Retired
6502 Lismore Dr
Browns Summit, NC 27214
Phone+1 336-312-4050

Education & Training

SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1984 - 1987
SUNY Upstate Medical UniversityResidency, Internal Medicine, 1980 - 1984
Icahn School of Medicine at Mount SinaiClass of 1980
State University of New York at New PaltzB.A., Biology, Cum Laude, 1973

Certifications & Licensure

FL State Medical License 1987 - 2025
NC State Medical License 1990 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
ABIMFellow of American College of Physicians

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2013
Healer of the Year NC Breast Cancer Coalition, 1997
Joseph B Stevens Award for Excellence in Teaching Program Moses Cone Hospital, 1994
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2012 Jun 18
Recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery Start of enrollment: 2010 Apr 12
Active, not recruiting
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Apr 08
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer Start of enrollment: 2013 Mar 07
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy Start of enrollment: 2017 Jul 14
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

5 citations
Pharmacy Student Monitoring of Direct Oral Anticoagulants.
Jennifer J. Kim, Hailey L. Hill, J. B. Groce, James M. Granfortuna, Tanya K. Makhlouf
Journal of Pharmacy Practice. 2018-01-24
3 citations
Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study.
James Granfortuna, Kaye Shoffner, S. Depasquale, Sejal Badre, Chet Bohac
Supportive Care in Cancer. 2018-01-19
1 citations
Re: Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):91...
Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani
Journal of Surgical Oncology. 2017-07-28

Journal Articles

Phase II Trial of CHIP in Previously Treated Patients with Small Cell Carcinoma of the Lung
Granfortuna, J.M., Poiesz, B.J., Comis, R.L., Ginsberg, S.J., et. AL, American J. of Clinical Oncology, 1/1/1989
Thromobotic Thrombocytopenia Purpura: Treatment with Plasmapheresis
Blitzer, J.B., Granfortuna, J.M., Gottlieb, A. J. et al, American J. of Hematology, 1/1/1987
Renal Infarction in Sickle Cell Disease
Granfortuna, J.M., Zamkoff, K., Urrutia E, American J. of Hematology, 1/1/1986

Abstracts/Posters

Transfusion Practice Patterns in Patients Receiving Myelosuppresive Chemotherapy for Nonmyeloid Cancer: Results from a Prospective Observational Study
C Bohac, J Granfortuna, K Shoffner, S DePasquale, X Sui, S Badre, C Olivera Brandao, JADPRO, Washington, DC, 1/1/2016
Hereditary Hemochromocytosis in Combination with Heterozygous Beta-Thalassemia or Spherocytosis
I.M. Lubin, V. Fairbanks, S.N. Thibideau, W.S. Harrill, J.M. Granfortuna, L.M. Silverman, E.M. Rohlfs, American Society of Hematology, 1/1/1998
Neoadjuvant MVAC for Locally Advanced Transitional Cell Carcinoma of the Bladder
Meisner, D. J., Makhuli, Z., Granfortuna, J.M., Dowley, S., Suggan, D., et. Al, ASCCO, 1/1/1989

Other

Neoadjuvant MVAC for the Treatment of Locally Advanced Urothelial Malignancy
Granfortuna, J.M., Duggan, D., Poiesz, B.J., Makuli, Z, Pilot Study
Suny Health Science Center, Syracuse, NY - 1/1/1987